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ABSTRACT
Although a new classification algorithm for systemic vasculitides was proposed by Watts et al. and the Chapel
Hill Consensus Conference (CHCC) was updated in 2012, there are currently no validated diagnostic criteria
for systemic vasculitides. The Diagnostic and Classification Criteria for Vasculitis study (DCVAS) is a global
study to develop and improve the diagnostic criteria for systemic vasculitides. The epidemiology of systemic
vasculitides differs widely among countries. For example, in the case of anti-neutrophil cytoplasmic antibody
(ANCA)-associated vasculitis, patients with microscopic polyangiitis (MPA) and with positivity for MPO-ANCA
are predominant in Asian countries, whereas patients with granulomatosis with polyangiitis (GPA) and with
positivity for PR3-ANCA are predominant in northern Europe and the United States. Interstitial lung disease
(ILD) occurs more frequently in Asian patients compared with patients in Europe. The incidence and the preva-
lence of large-vessel vasculitis also differ significantly. Giant cell arteritis (GCA) occurs frequently in northern
Europe, unlike Takayasu arteritis (TAK). The ethnic and regional differences in the incidence, prevalence and
clinical characteristics of patients with vasculitis should be recognized when we diagnose and treat patients
with vasculitis using criteria, and should also be considered when interpreting the results from clinical studies.
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A HISTORY OF THE CLASSIFICATIONS AND
DEFINITIONS OF VASCULITIDES
Systemic vasculitides are pathologically identified by
the inflammation of blood vessel walls, and cause
various organ disorders depending on the size of the
affected blood vessels. Since Kussmaul and Maier re-
ported an autopsy case with polyarteritis nodosa in
1866, several types of systemic necrotizing vasculitis
have been reported. The first classification of vasculi-
tis was proposed by Zeek in 1952.1,2 After the disease
concept of Wegener’s granulomatosis (WG) was re-
ported,3 DeRemee et al. proposed the ELK classifica-
tion (upper respiratory tract, lung and kidney) for
WG.4
In 1990, the American College of Rheumatology
(ACR) published criteria for classifying vasculitides
to facilitate communication among researchers.5 The
criteria classified seven types of primary vasculitides;
giant cell arteritis (GCA), Takayasu arteritis (TAK),
WG, Churg-Strauss syndrome (CSS), polyarteritis no-
dosa (PAN), Henoch-Schönlein purpura and hyper-
sensitivity vasculitis.6-12 The criteria for PAN, WG and
CSS have a specificity of 86.6%, 92.0% and 99.7%, re-
spectively, with a respective sensitivity of 82.2%, 88.2%
and 85.0%. However, the criteria were established be-
fore the general use of antineutrophil cytoplasmic an-
tibody (ANCA) testing, and the most significant prob-
lem with these criteria is that they do not distinguish
microscopic polyangiitis (MPA) from PAN. Rao et al.
reported the limitations of the criteria for the diagno-
sis of vasculitis.13
In 1994, Jennette et al. published the results of the
Chapel Hill Consensus Conference (CHCC) on the
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Fig.　1　The EMA algorithm. Reproduced with permission 
from: Watts R, et al. Development and validation of a con-
sensus methodology for the classifi cation of the ANCA-
associated vasculitides and polyarteritis nodosa for epide-
miological studies. Ann Rheum Dis 2007; 66: 222-7. ACR, 
American College of Rheumatology; CHCC, Chapel Hill 
Consensus Conference; PSV, primary systemic vasculiti-
des; EGPA, eosinophilic granulomatosis with polyangiitis 
(Churg-Strauss syndrome); GPA, granulomatosis with poly-
angiitis (Wegener’s granulomatosis); MPA, microscopic 
polyangiitis; MPO, myeloperoxidase; PR3, proteinase 3; 
cPN, classical polyarteritis nodosa.
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Nomenclature of Systemic Vasculitis.14 They adopted
names and definitions of vasculitides based on the
size of the affected vessels, and categorized vasculiti-
des into large-vessel vasculitis, medium-vessel vascu-
litis and small-vessel vasculitis, including MPA. Al-
though they emphasized that the nomenclature and
the definitions did not provide diagnostic or classifica-
tion criteria, both the ACR criteria and CHCC defini-
tions have been used in parallel to diagnose vasculitis
by many clinicians, leading to an overlapping diagno-
sis of PAN and MPA.
Sorensen et al. created new criteria by using the
CHCC 1994 definitions and surrogate parameters to
diagnose primary vasculitis,15 although a prospective
vasculitis register found that the Sorensen diagnostic
criteria for MPA were not very useful.16
THE EUROPEAN MEDICINES AGENCY AL-
GORITHM
In 2007, Watts and colleagues proposed a new four-
step algorithm for the classification of ANCA-
associated vasculitides and PAN (the European Medi-
cines Agency algorithm: EMA algorithm).17 The algo-
rithm utilizes the ACR 1990 criteria, CHCC 1994 defi-
nitions and surrogate markers to sequentially classify
CSS, WG, MPA and PAN. In the algorithm, the ACR
criteria and Lanham criteria for CSS are applied first
(step 1) to select patients with CSS. As step 2, the
ACR criteria for WG, the CHCC definitions and the
surrogate makers for WG are applied to diagnose
WG. If histological evidence is not available, but sur-
rogate markers are present and ANCA is positive,
then patients are classified as having WG. The CHCC
1994 definitions for MPA and surrogate markers for
renal vasculitis distinguish MPA from PAN (Steps 3
and 4) (Fig. 1). Because of the poor specificity, the al-
gorithm did not include the ACR criteria for PAN.
The algorithm obtained classifiers’ agreement in
92.3% of the cases of WG, 93.4% of cases of MPA,
95.4% of cases of CSS and 76.9% of the cases of PAN.
Two reports were published that evaluated the algo-
rithm, and both of them concluded that the algorithm
was useful and practical for epidemiological stud-
ies.18,19
THE CHAPEL HILL CONSENSUS CONFER-
ENCE NOMENCLATURE OF VASCULITIDES
(CHCC 2012)
In January 2013, the international CHCC published
revised nomenclature and definitions of vasculitides
(CHCC 2012). They emphasized again that CHCC is
a nomenclature system, and not a classification sys-
tem for clinical research, nor a diagnostic system that
can be used to direct clinical management.20 In addi-
tion to the three categories described in the CHCC
1994 (large-vessel vasculitis, medium-vessel vasculitis
and small-vessel vasculitis), they added new four
categories; variable vessel vasculitis, single organ
vasculitis, vasculitis associated with systemic disease
and vasculitis associated with probable etiology (Fig.
2, Table 1).
Large-vessel vasculitis, including TAK and GCA,
was defined as vasculitis affecting the aorta and its
major branches more often than other vasculitides,
whereas any size artery might be affected. It was con-
cluded that these types of arteritis could not be distin-
guished by pathological findings, except for the dif-
ference in the age of onset.
Medium-vessel vasculitis, including PAN and
Kawasaki disease (KD), was defined as vasculitis af-
fecting the main visceral arteries and their branches.
PAN is defined as necrotizing arteritis of the medium
or small arteries without glomerulonephritis or vascu-
litis in the arterioles, capillaries or venules, and the
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Fig.　2　A diagram showing the CHCC 2012 based on the size of vessels. Reproduced with per-
mission from: Jennette JC, et al. 2012 revised International Chapel Hill Consensus Conference 
Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11. CHCC, Chapel Hill Consensus 
Conference; GBM, glomerular basement membrane.
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criteria clearly stated that it could not be associated
with ANCA based on a report describing that ANCA
is typically absent in patients with PAN.21
Among small-vessel vasculitides, ANCA-associated
vasculitis (AAV) was distinguished from the other
types of small-vessel vasculitis called “immune com-
plex vasculitis,” including anti-glomerular basement
membrane (anti-GBM) disease, cryoglobulinemic
vasculitis, IgA vasculitis and hypocomplementemic
urticarial vasculitis (anti-C1q vasculitis). Patients
clinically considered to have AAV without ANCA
were referred to as having ANCA-negative AAV. Im-
mune complex small-vessel vasculitis is defined as
vasculitis with moderate to marked vessel wall depos-
its of immunoglobulin and complement components,
predominantly affecting small vessels. These deposits
differ from the few or no immune deposits in vessel
walls, which is characteristic for ANCA-associated
vasculitides. When appropriate, immune complex vas-
culitis can be categorized as vasculitis associated with
probable etiologies (e.g., hepatitis C virus-associated
cryoglobulinemic vasculitis) or as a vasculitis associ-
ated with systemic disease (e.g., lupus vasculitis or
rheumatoid vasculitis).
Variable vessel vasculitis is defined as vasculitis
with no predominant size of the affected vessels.
Behçet’s disease and Cogan’s syndrome are catego-
rized as variable vessel vasculitis, rather than vasculi-
tis associated with a systemic disease.
In the CHCC 2012 definitions, efforts were made to
replace eponyms with suitable non-eponymous terms.
The eponyms “Wegener’s granulomatosis” and
“Churg-Strauss syndrome” were replaced by granulo-
matosis with polyangiitis (GPA) and eosinophilic
granulomatosis with polyangiitis (EGPA). The epo-
nym Henoch-Schönlein purpura was also replaced by
IgA vasculitis. “Goodpasture’s syndrome” has been
used in the past for the clinical entity associated with
diffuse pulmonary hemorrhage and rapid progressive
glomerulonephritis with anti-GBM antibodies, but the
use of “anti-GBM disease” was advocated in the
CHCC 2012. These changes in the names of vasculiti-
des have already been widely accepted. The names
“Takayasu arteritis” and “Kawasaki disease” re-
mained, because there were no suitable non-
eponymous terms to describe these diseases. The
eponyms “Behçet’s disease” and “Cogan’s syndrome”
were added as types of variable vessel vasculitis.
THE ACREULAR DIAGNOSTIC AND CLAS-
SIFICATION CRITERIA FOR VASCULITIS
STUDY (DCVAS)
Although the ACR 1990 criteria and CHCC 2012 defi-
nitions have been widely used as diagnostic criteria
for systemic vasculitis by clinical researchers and
physicians, there are currently no appropriate criteria
to diagnose systemic vasculitis. The diagnostic crite-
ria with updated classifications based on the in-
creased understanding of the pathophysiology, and
with newly widespread diagnostic test tools, are re-
quired for not only clinical researchers, but also for
practicing clinicians.
Lionaki et al. found substantial discrepancies in the
allocation of patients between the CHCC definitions
Katsuyama T et al.
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Table　1　Names for vasculitides adopted by CHCC 2012
I. Large-vessel vasculitis (LVV) Takayasu arteritis (TAK)
Giant cell arteritis (GCA)
II. Medium-vessel vasculitis (MVV) Polyarteritis nodosa (PAN)
Kawasaki disease (KD)
III. Small-vessel vasculitis (SVV) ANCA-associated vasculitis (AAV)
Microscopic polyangiitis (MPA)
Granulomatosis with polyangiitis (GPA)
Eosinophilic granulomatosis with polyangiitis (EGPA)
Immune complex small-vessel vasculitis
Anti-GBM disease
Cryoglobulinemic vasculitis (CV)
IgA vasculitis (IgAV)
Hypocomplementemic urticarial vasculitis (HUV)
Variable vessel vasculitis (VVV) Behçet’s disease (BD)
Cogan’s syndrome (CS)
Single-organ vasculitis (SOV) Cutaneous leukocytoclastic angiitis
Cutaneous arteritis
Primary central nervous system vasculitis
Isolated aortitis
Others
Vasculitis associated with systemic disease Lupus vasculitis
Rheumatoid vasculitis
Sarcoid vasculitis
Others
Vasculitis associated with probable etiology Hepatitis C virus-associated cryoglobulinemic vasculitis
Hepatitis B virus-associated vasculitis
Syphilis-associated aortitis
Drug-associated immune complex vasculitis
Drug-associated ANCA-associated vasculitis
Cancer-associated vasculitis
Others
Adapted with permission from: Jennette JC, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculi-
tides. Arthritis Rheum 2013; 65: 1-11. ANCA, anti-neutrophil cytoplasmic antibody; GBM, glomerular basement membrane.
and the EMA algorithm in a retrospective study of
502 patients with ANCA-associated vasculitis.22 Sixty-
four percent of the cases classified as MPA by the
CHCC definitions were categorized as having GPA by
the algorithm, and the proportion of patients consid-
ered to have GPA by the algorithm was significantly
higher than those in the CHCC definition (65% vs.
23%, p < 0.0001). The authors of that study also re-
vealed that neither system could predict relapse
among patients with ANCA-associated vasculitis with
renal disease, and that the ANCA phenotype could
provide a more useful tool for predicting relapse.
Lyons et al. investigated the genetic basis of ANCA-
associated vasculitis, and provided preliminary sup-
port for the concept that proteinase 3 (PR3)-ANCA-
associated vasculitis and myeloperoxidase (MPO)-
ANCA-associated vasculitis are distinct autoimmune
syndromes.23
Recently, Hoffman and Calabrese published a re-
view article suggesting that the classification of vas-
culitis merely based on the size of vessels could fail to
consider that the vessels of the same caliber in differ-
ent locations have specialized roles in response to
stimuli, injury and repair that determine the disease
patterns.24 They also stated that an improved under-
standing of the unique territorial vulnerabilities of
vessels could form the basis of new hypotheses for
the etiopathogenesis of vasculitis.
The imaging techniques used as diagnostic tools
for systemic vasculitis have also developed rapidly.
The usefulness of computed tomographic angiogra-
phy (CTA) and magnetic resonance angiography
(MRA) in patients with TAK has been reported.25,26
The use of ultrasound and positron emission to-
mography CT (PET-CT) may also be established to
diagnose and evaluate TAK and GCA.27-30
Classification of Systemic Vasculitides
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The ACR and the European league against rheuma-
tism (EULAR) have made an international effort to
develop new diagnostic criteria for systemic vasculiti-
des. The study is named the “Diagnostic and Classifi-
cation Criteria of Vasculitis (DCVAS)” study, and the
goal of the study is to develop and improve the diag-
nostic criteria for ANCA-associated vasculitis, PAN,
TAK and GCA.31,32 They will analyze more than 2,000
patients with vasculitis not only based on the tradi-
tional approach involving vessel size for the classifica-
tion of vasculitis, but also on clinical data, ANCA test-
ing, biopsy and imaging data.31 The first patient was
recruited into the DCVAS in 2010, and the develop-
ment of a new internationally unified diagnostic and
classification criteria for both researchers and clini-
cians is expected.
EPIDEMIOLOGY OF ANCA-ASSOCIATED
VASCULITIS
The regional and ethnic differences in the clinical fea-
tures of patients with primary systemic vasculitis
have been well known. For example, in the case of
ANCA-associated vasculitis, there have been some re-
ports suggesting that the incidence and clinical char-
acteristics differ geographically. The incidence and
the prevalence of GPA are significantly higher in re-
ports from northern Europe (Norway and Germany),
while MPA is predominant in reports from southern
Europe (Spain),33-36 whereas the incidence of GPA
and MPA were equal in a report from Sweden.37
Fujimoto et al. performed a population-based study
to show the incidence of primary renal vasculitis, and
revealed that the incidence of renal vasculitis did not
differ between Japan and European countries, al-
though patients with GPA or EGPA were not de-
tected in the study in Japan.38 A prospective study
was subsequently performed to compare the inci-
dence and characteristics of ANCA-associated vascu-
litis between Japan and Europe using the same defini-
tions.39 Patients were classified using the EMA algo-
rithm. There was no significant difference in the an-
nual incidence of ANCA-associated vasculitis between
Japan and the UK (22.6 vs. 21.8million adults),
whereas the annual incidence of MPA in Japan was
higher than that in the UK (18.2 vs. 6.5million
adults), while GPA was predominant in the UK (14.3
million adults) compared with the incidence in Japan
(2.1million adults). There were also significant dif-
ferences in the ANCA phenotype; the ratio of
pANCAMPO-positive patients was significantly
higher in Japan than the ratio in the UK (83.7% and
30.0%, respectively, p < 0.001), while there were sig-
nificantly fewer cANCAPR3-positive patients in Ja-
pan (7.0% and 58.0%, respectively, p < 0.001). A high
ratio of MPO-ANCA positivity to PR3-ANCA positivity
was also reported in other Asian countries.40,41
In 2014, Sada and colleagues published the results
of a nationwide prospective cohort study of remission
induction therapy in Japanese patients with AAV
(RemIT-JAV), and also showed that MPO-ANCA-
positive MPA, including renal-limited vasculitis, was
the most common form of ANCA-associated vasculitis
in Japanese patients, and that one-half of the patients
with GPA were positive for MPO-ANCA in Japan.42
The reports from China and Taiwan also revealed
that MPA was predominant among the patients in
these countries with ANCA-associated vasculitis.41,43
Besides the differences in the incidence and the
prevalence, the characteristics of the affected organs
in patients with ANCA-associated vasculitis also vary
widely between Europe and Asian countries. Sugi-
yama and colleagues published a report describing
the characteristics of MPA and GPA in Japan using
the database of the Ministry of Health, Labour and
Welfare (MHLW) from 2006 to 2008.44 This study re-
vealed that 73.7% of Japanese patients with MPA had
pulmonary involvement and 11.3% presented with pul-
monary hemorrhage. A high prevalence of interstitial
pneumonia in patients with ANCA-associated vasculi-
tis in Asian countries was also indicated in other ret-
rospective studies.41 Of note, less than 10% of patients
with ANCA-associated vasculitis in European coun-
tries had ILD.45,46 Some reports previously indicated
that interstitial lung diseases (ILD) developed more
frequently in MPO-ANCA-positive patients with
ANCA-associated vasculitis than in PR3-ANCA-
positive patients,47,48 suggesting that the differences
in the prevalence of ILD between Asia and Europe
may results from the ANCA phenotype.
The RemIT-JAV study revealed that ANCA-
associated vasculitis patients with ILD tended to be
categorized as having lower disease activity by the
Birmingham Vasculitis Activity Score (BVAS).42 The
BVAS is a standard tool to evaluate the clinical dis-
ease activity in patients with systemic vasculitis, and
is widely used not only by physicians, but also by
clinical researchers.49 The BVAS is based on symp-
toms and signs in nine separate organs.50 It is note-
worthy that ILD is not included in the BVAS scoring
system. Although a report concluded that the BVAS
was a useful tool for determining the disease activity
and outcome in Japanese patients with MPA,51 fur-
ther investigations are required to analyze the long-
term prognosis in ANCA-associated vasculitis pa-
tients with ILD, and to clarify whether the BVAS scor-
ing system can be applied to all patients with ANCA-
associated vasculitis in terms of the variety of re-
gional and ethnic differences in the clinical character-
istics.
Sreih et al. published a report comparing the clini-
cal characteristics of patients with ANCA-associated
vasculitis between Hispanics and Caucasians living in
the same geographical area.52 They revealed that His-
panics with ANCA-associated vasculitis present with
more severe disease activity and more severe organ
injuries compared to Caucasians. Although some
Katsuyama T et al.
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studies have been performed to analyze the genetic
background of ANCA-associated vasculitides,53 fur-
ther research in different ethnic groups is required to
reveal the effects of genetic factors on the clinical
characteristics and prognosis of ANCA-associated
vasculitides.
EPIDEMIOLOGY OF POLYARTERITIS NO-
DOSA
The populations of patients with PAN in some old re-
ports were not homogeneous because they included
patients with MPA; hence it is difficult to discuss the
ethnic and regional differences in the incidence,
prevalence and the clinical characteristics of PAN.
The annual incidence of PAN in Spain diagnosed us-
ing the CHCC 1994 and in Sweden using the EMA al-
gorithm were both 0.90million adults,35,37 and the
prevalence was approximately 30million adults in
Europe.54,55 Pagnoux et al. described the characteris-
tics of a large number of patients with PAN, which
was well distinguished from MPA.56 Of the 348 pa-
tients with PAN, 123 patients had hepatitis B virus
(HBV)-related PAN. The mean age at diagnosis was
51.2 ± 17.3 years (±SD), and the ratio of males to fe-
males was 1.7 (220128). Fibrinoid necrosis of inter-
stitial medium-sized arteries was detected in four of
the 11 patients who underwent a renal biopsy. They
also revealed that the patients with HBV-related PAN
presented more severe disease activity compared
with patients with non-HBV-related PAN. However,
relapse occurred more frequently in patients with
non-HBV-related PAN than in patients with HBV-
related PAN. Recently, it was reported that loss-of-
function mutations of adenosine deaminase 2 (ADA2)
could cause PAN vasculopathy.57 This may underlie
some of the differences in different populations.
EPIDEMIOLOGY OF LARGE-VESSEL VAS-
CULITIDES
TAK was first reported by Takayasu in 1908.58,59 Al-
though patients with TAK have been reported from
all over the world, the prevalence and the annual inci-
dence of TAK have been limited.34,60-63 Previous re-
ports revealed that patients with TAK are predomi-
nant in Asian countries compared with Western coun-
tries, although the low prevalence of TAK makes it
difficult to estimate the accurate incidence and preva-
lence of the disease. The guidelines for the manage-
ment of vasculitis syndrome by the Japanese Circula-
tion Society (JCS 2008) reported that more than 5,000
patients with TAK were registered in the MHLW reg-
istry, so the prevalence was more than 0.004%.64
Moreover, the distribution of vascular involvement
reportedly differs among regions.65 In Japan and
South America, cervical and thoracic arterial lesions
are prevalent, whereas abdominal lesions are more
common in Israel and other Asian countries.66
The HLA-B52 haplotype is well known to be closely
associated with TAK not only in Japan, but also in
other countries.67-72 In Japan, the prevalence of the
HLA-B52 allele in healthy controls is higher com-
pared with that in other countries, which might be re-
sponsible for the high prevalence of TAK and the
higher prevalence of HLA-B52 in patients with TAK
than in other countries. The correlation of other HLA
alleles with TAK has been also reported.72,73
On the other hand, the incidence and prevalence of
giant cell arteritis (GCA) is significantly higher in
northern Europeans than in southern Europeans and
Asians.74 The annual incidence of GCA in Scandina-
vian countries was reported to be over 20100,000
people over the age of 50,75-79 whereas a lower inci-
dence rate of approximately 10100,000 was reported
in Italy and Spain.80,81 In Asia, much lower incidence
and prevalence rates were reported.82 Kobayashi et
al. reported the results of a nationwide survey, and
showed that the point prevalence of GCA in Japan
was 690 patients in 1997.83
Some genetic factors might affect these differences
in the incidence and prevalence of GCA. For exam-
ple, patients with GCA showed an increased fre-
quency of DR4 compared with controls in a report
from Italy.80 The HLA-DRB1*0401 and HLA-DRB1*
0404 alleles (components of the DR4 gene) were pre-
dominantly detected in GCA patients, and were less
frequently detected in Japanese healthy controls com-
pared with American healthy controls.83-85 This might
explain one of the reasons for the low incidence and
prevalence of GCA in Japan.
A study of a large number of Japanese patients with
TAK showed a significant female predominance (the
female to male ratio was eight to one), and some re-
ports from other countries indicated the same results.
However, a report comparing the characteristics of
patients with TAK in Japan and India revealed a sig-
nificantly lower ratio of female to male patients with
TAK in India than the ratio in Japan.86 GCA affects fe-
males two to three times more often than males, and
this rate is similar all over the world.
Some studies have demonstrated an overall in-
crease in the incidence of GCA.81,87 The increase
might be dependent on the improvements in the diag-
nostic tools, especially imaging tools such as CTA,
MRA and PET. The development of new diagnostic
criteria for TAK and GCA is required, and as de-
scribed above, the DCVAS is trying to develop and
improve the criteria for systemic vasculitides, includ-
ing large-vessel vasculitis.
CONCLUSIONS
We herein reviewed the current classification criteria
and definitions for systemic vasculitides. These are
used to categorize and diagnose patients with vasculi-
tis, although they were not developed as diagnostic
criteria. Hence, international groups are making an
effort to establish new internationally unified diagnos-
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tic and classification criteria. Global evidence has
been established for the treatment of some types of
systemic vasculitis based on randomized controlled
trials.88-93 However, the ethnic and regional differ-
ences in the incidence, prevalence and clinical char-
acteristics of patients with vasculitis should be recog-
nized when we apply the results of studies to each pa-
tient. Further international studies are required to re-
veal that how the ethnic and regional differences are
related to pathogenesis, and to establish individualiz-
ing therapies for systemic vasculitides.
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